Affimed Announces Oral Presentation Of Phase 1/2 Data From AFM13 In Combination With Allogeneic NK Cells At The 2023 ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Affimed N.V. (NASDAQ:AFMD) announced the presentation of Phase 1/2 data from AFM13 in combination with allogeneic NK cells at the 2023 ASH Annual Meeting. The treatment showed a 94.4% objective response rate and a 72.2% complete response rate in 36 patients with CD30-positive lymphoma. The company also announced two upcoming presentations on its lead innate cell engager (ICE®) AFM13 at the ASH 2023 Annual Meeting.
November 02, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Affimed N.V. announced positive Phase 1/2 data from AFM13 in combination with allogeneic NK cells, which could potentially boost investor confidence and the company's stock price.
The announcement of positive Phase 1/2 data from AFM13 in combination with allogeneic NK cells is a significant milestone for Affimed N.V. This could potentially boost investor confidence in the company's research and development capabilities, and in turn, positively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100